{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T13:17:46Z","timestamp":1771679866949,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12931-016-0361-4","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T22:01:45Z","timestamp":1462312905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT\u00ae trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Bartolom\u00e9 R.","family":"Celli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Decramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dacheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Metzdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guus M.","family":"Asijee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald P.","family":"Tashkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,4]]},"reference":[{"key":"361_CR1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","volume":"356","author":"PM Calverley","year":"2007","unstructured":"Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775\u201389.","journal-title":"N Engl J Med"},{"key":"361_CR2","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","volume":"359","author":"DP Tashkin","year":"2008","unstructured":"Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543\u201354.","journal-title":"N Engl J Med"},{"key":"361_CR3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1465-9921-14-40","volume":"14","author":"RA Wise","year":"2013","unstructured":"Wise RA, Anzueto A, Calverley P, Dahl R, Dusser D, Pledger G, et al. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res. 2013;14:40.","journal-title":"Respir Res"},{"key":"361_CR4","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1183\/09031936.00087312","volume":"41","author":"J Vestbo","year":"2013","unstructured":"Vestbo J, Anderson J, Brook RD, Calverley PM, Celli BR, Crim C, et al. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur Respir J. 2013;41:1017\u201322.","journal-title":"Eur Respir J"},{"key":"361_CR5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/CIRCOUTCOMES.113.000149","volume":"7","author":"G Gomez","year":"2014","unstructured":"Gomez G, Gomez-Mateu M, Dafni U. Informed choice of composite end points in cardiovascular trials. Circ Cardiovasc Qual Outcomes. 2014;7:170\u20138.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"11","key":"361_CR6","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.acvd.2015.06.001","volume":"108","author":"G Loncar","year":"2015","unstructured":"Loncar G, Barthelemy O, Berman E, Kerneis M, Petroni T, Payot L, et al. Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention. Arch Cardiovasc Dis. 2015;108(11):554\u201362.","journal-title":"Arch Cardiovasc Dis"},{"key":"361_CR7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1745-6215-13-61","volume":"13","author":"CS Merle","year":"2012","unstructured":"Merle CS, Sismanidis C, Sow OB, Gninafon M, Horton J, Lapujade O, et al. A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the gatifloxacin for TB (OFLOTUB) project. Trials. 2012;13:61.","journal-title":"Trials"},{"key":"361_CR8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/dom.12226","volume":"16","author":"TR Einarson","year":"2014","unstructured":"Einarson TR, Garg M, Kaur V, Hemels ME. Composite endpoints in trials of type-2 diabetes. Diabetes Obes Metab. 2014;16:492\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"Pt 5","key":"361_CR9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/brain\/122.5.871","volume":"122","author":"GR Cutter","year":"1999","unstructured":"Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(Pt 5):871\u201382.","journal-title":"Brain"},{"issue":"2","key":"361_CR10","first-page":"20141127","volume":"11","author":"CK Naber","year":"2015","unstructured":"Naber CK, Pyxaras SA, Nef H, IJsselmuiden AJ, Briguori C, Schlundt C, et al. Final results of a self-apposing paclitaxel-eluting stent fOr the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study. EuroIntervention. 2015;11(2):20141127\u201306. doi: 10.4244\/EIJY15M06_02 .","journal-title":"EuroIntervention"},{"issue":"Suppl 1","key":"361_CR11","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1097\/01.hjh.0000467402.25796.00","volume":"33","author":"C Chi","year":"2015","unstructured":"Chi C, Tai C, Wang J, Protogerou A, Blacher J, Safar ME, et al. 2A.04: Whether ACE inhibitor\/ARB combined with CCB is superior to other combinations? A meta-analysis in 20,669 hypertensives. J Hypertens. 2015;33 Suppl 1:e19\u201320.","journal-title":"J Hypertens"},{"key":"361_CR12","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1056\/NEJM200012283432601","volume":"343","author":"Lung Health Study Research Group","year":"2000","unstructured":"Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343:1902\u20139.","journal-title":"N Engl J Med"},{"key":"361_CR13","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa0900928","volume":"363","author":"FC Sciurba","year":"2010","unstructured":"Sciurba FC, Ernst A, Herth FJ, Strange C, Criner GJ, Marquette CH, et al. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med. 2010;363:1233\u201344.","journal-title":"N Engl J Med"},{"key":"361_CR14","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(09)61298-8","volume":"374","author":"M Decramer","year":"2009","unstructured":"Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374:1171\u20138.","journal-title":"Lancet"},{"key":"361_CR15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12931-015-0216-4","volume":"16","author":"DP Tashkin","year":"2015","unstructured":"Tashkin DP, Leimer I, Metzdorf N, Decramer M. Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT\u00ae trial. Respir Res. 2015;16:65.","journal-title":"Respir Res"},{"key":"361_CR16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.rmed.2011.10.009","volume":"106","author":"LP McGarvey","year":"2012","unstructured":"McGarvey LP, Magder S, Burkhart D, Kesten S, Liu D, Manuel RC, et al. Cause-specific mortality adjudication in the UPLIFT\u00ae COPD trial: findings and recommendations. Respir Med. 2012;106:515\u201321.","journal-title":"Respir Med"},{"key":"361_CR17","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1164\/rccm.200703-456SO","volume":"176","author":"KF Rabe","year":"2007","unstructured":"Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532\u201355.","journal-title":"Am J Respir Crit Care Med"},{"key":"361_CR18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0140-6736(13)61454-3","volume":"382","author":"AH Gershlick","year":"2013","unstructured":"Gershlick AH, Banning AP, Myat A, Verheugt FW, Gersh BJ. Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention? Lancet. 2013;382:624\u201332.","journal-title":"Lancet"},{"key":"361_CR19","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jacc.2015.04.067","volume":"66","author":"AH Gershlick","year":"2015","unstructured":"Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, et al. Reply: Complete revascularization in patients undergoing primary percutaneous coronary intervention for STEMI: is it really what we should be doing? J Am Coll Cardiol. 2015;66:332\u20133.","journal-title":"J Am Coll Cardiol"},{"key":"361_CR20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","volume":"383","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2014;383:321\u201332.","journal-title":"Lancet"},{"key":"361_CR21","first-page":"239","volume":"10","author":"DM Halpin","year":"2015","unstructured":"Halpin DM, Dahl R, Hallmann C, Mueller A, Tashkin D. Tiotropium HandiHaler\u00ae and Respimat\u00ae in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:239\u201359.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"361_CR22","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.rmed.2014.07.011","volume":"108","author":"JA Wedzicha","year":"2014","unstructured":"Wedzicha JA, Dahl R, Buhl R, Schubert-Tennigkeit A, Chen H, D'Andrea P, et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med. 2014;108:1498\u2013507.","journal-title":"Respir Med"},{"key":"361_CR23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1378\/chest.12-2332","volume":"144","author":"WB White","year":"2013","unstructured":"White WB, Cooke GE, Kowey PR, Calverley PM, Bredenbroker D, Goehring UM, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest. 2013;144:758\u201365.","journal-title":"Chest"},{"key":"361_CR24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1752-699X.2010.00198.x","volume":"5","author":"J Vestbo","year":"2011","unstructured":"Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J. 2011;5:44\u20139.","journal-title":"Clin Respir J"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-016-0361-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T08:38:40Z","timestamp":1498293520000},"score":1,"resource":{"primary":{"URL":"http:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-016-0361-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,4]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1186\/s12931-016-0361-4","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,4]]},"article-number":"48"}}